Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We performed a meta-analysis to evaluate the risk of venous thromboembolism (VTE) in pregnant women with essential thrombocythemia. Twenty-one trials and 756 pregnancies met inclusion criteria. The absolute VTE risk in the antepartum period is not above a threshold where low-molecular-weight heparin (LMWH) prophylaxis is clearly indicated or below a threshold where LMWH should be withheld (2.5%; 95% CI, 1.3-4.3). Postpartum, the absolute VTE risk is above a threshold where postpartum LMWH prophylaxis should be considered (4.4%; 95% CI, 1.2-9.5).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2016-09-728006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Completion pancreatectomy for postoperative complications after pancreatoduodenectomy].
Khirurgiia (Mosk)
September 2025
Saint Petersburg State University, Saint Petersburg, Russia.
Objective: To analyze the most well-known studies devoted to completion pancreatectomy (CP) for postoperative complications after pancreatoduodenectomy.
Material And Methods: We analyzed original articles and reviews between 1992 and 2023 (number of patients ≥5 (5-120)).
Results: Mean blood loss in CP ranged from 500 to 2180 ml, surgery time - from 144 to 340 min.
Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.
N Engl J Med
September 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.
Methods: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib.
Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients.
Cancer Med
September 2025
School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
Introduction: Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients, and a substantial number of patients are being treated with oral anticoagulants. We aim to assess the comparative effectiveness of direct oral anticoagulants (DOACs) compared to warfarin for VTE treatment in cancer patients.
Methods: In this retrospective cohort study, we included 2,367 cancer patients who are new users of oral anticoagulants (OACs) for VTE treatment from 2009 to 2021 in NHS Scotland.
Cerebral Venous Thrombosis:Current Status and Challenges.
Brain Behav
September 2025
Department of neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: Cerebral venous thrombosis (CVT) is a stroke type that primarily affects young individuals, with various risk factors and complex mechanisms. It accounts for 0.5% to 3% of all stroke cases and can significantly impact daily activities and quality of life.
View Article and Find Full Text PDFThe complex and hazardous course for heterotaxy-associated congenital heart disease.
JTCVS Open
August 2025
Division of Cardiothoracic Surgery, Department of Surgery, University of Southern California, Los Angeles, Calif.
Objective: Patients with heterotaxy-associated congenital heart disease often require multiple operations, which may have a cumulative effect on their outcomes. This study aimed to define the cardiac surgical course in a large cohort and identify longitudinal risk factors for death/transplant.
Methods: All patients with heterotaxy-associated congenital heart disease who underwent cardiac surgery at one institution from 2005 to 2022 were retrospectively reviewed.